Raisz L G, Alander C B, Fall P M, Simmons H A
Division of Endocrinology and Metabolism, University of Connecticut Health Center, Farmington 06032.
Endocrinology. 1990 Feb;126(2):1076-9. doi: 10.1210/endo-126-2-1076.
Although most studies show that prostaglandin E2 (PGE2) is the most potent and effective of the prostanoids in bone, recent data in cell culture suggest that PGF2 alpha may have unique effects, particularly on cell replication. The present study was undertaken to compare the effects of PGF2 alpha and PGE2 in cultured neonatal mouse parietal bones by simultaneous measurement of bone resorption as release of previously incorporated 45Ca, bone formation as incorporation of [3H]proline into collagenase-digestible (CDP) and noncollagen protein, and DNA synthesis as incorporation of [3H]thymidine. PGF2 alpha was less effective than PGE2 as a stimulator of bone resorption, and its effects were partially inhibited by indomethacin and markedly inhibited by glucocorticoids. In contrast, the resorptive response to PGE2 was unaffected by indomethacin and only partially inhibited by cortisol. PGF2 alpha had little effect on bone formation, in contrast to the biphasic effect of PGE2, which inhibited labeling of CDP in the absence of cortisol and stimulated CDP labeling in the presence of cortisol. PGF2 alpha increased thymidine incorporation into DNA, but the effect was smaller than that of PGE2 and was inhibited by indomethacin. These observations suggested that PGF2 alpha might act in part by stimulating PGE2 production. By RIA, PGE2 concentrations were increased in the medium of bones treated with PGF2 alpha, and this increase was blocked by indomethacin. By HPLC, bones prelabeled with [3H]arachidonic acid showed an increase in labeled PGE2 release, and RIA showed an increase in PGE2 after PGF2 alpha treatment. These results indicate that PGF2 alpha is a relatively weak agonist in bone compared to PGE2 and that some of the effects of PGF2 alpha on bone resorption, formation, and cell replication may be mediated by an increase in endogenous PGE2 production.
尽管大多数研究表明前列腺素E2(PGE2)是前列腺素类中对骨骼作用最强且最有效的,但细胞培养中的最新数据表明前列腺素F2α(PGF2α)可能具有独特作用,尤其是对细胞复制的作用。本研究旨在通过同时测量骨吸收(以前掺入的45Ca的释放)、骨形成([3H]脯氨酸掺入胶原酶可消化的(CDP)和非胶原蛋白中)以及DNA合成([3H]胸腺嘧啶核苷的掺入),比较PGF2α和PGE2对培养的新生小鼠顶骨的影响。作为骨吸收的刺激剂,PGF2α的效果不如PGE2,其作用部分被吲哚美辛抑制,而被糖皮质激素显著抑制。相比之下,对PGE2的吸收反应不受吲哚美辛影响,仅被皮质醇部分抑制。与PGE2的双相作用相反,PGF2α对骨形成几乎没有影响,PGE2在无皮质醇时抑制CDP标记,在有皮质醇时刺激CDP标记。PGF2α增加了胸腺嘧啶核苷掺入DNA,但作用小于PGE2,且被吲哚美辛抑制。这些观察结果表明,PGF2α可能部分通过刺激PGE2产生而起作用。通过放射免疫分析(RIA),用PGF2α处理的骨骼培养基中PGE2浓度升高,且这种升高被吲哚美辛阻断。通过高效液相色谱(HPLC),用[3H]花生四烯酸预标记的骨骼显示标记的PGE2释放增加,RIA显示PGF2α处理后PGE2增加。这些结果表明,与PGE2相比,PGF2α在骨骼中是一种相对较弱的激动剂,并且PGF2α对骨吸收、形成和细胞复制的一些作用可能由内源性PGE2产生的增加介导。